Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Sevelda

Showing results (121-130 of 148) with videos related to

Pageof 15
Sort By:
Cancer|May 15, 1993
In vitro and in vivo evaluation of the combination of cisplatin and its analogue carboplatin for platinum dose intensification in ovarian carcinomaC Dittrich, P Sevelda, M Baur, et al.
Anticancer Research|September 1, 1994
pS2 protein status fails to be an independent prognostic factor in an average breast cancer populationP Speiser, J Stolzlechner, K Haider, et al.
Lancet (London, England)|March 3, 1990
Adjuvant tamoxifen in postmenopausal stage II breast cancer five years onJ Mikl, P Aiginger, K Czerwenka, et al.
Geburtshilfe Und Frauenheilkunde|May 1, 1991
[Effect of various factors on survival after recurrent and/or metastatic breast cancer]P Sevelda, I Kührer, C C Zielinski, et al.
International Journal of Cancer|January 15, 1994
Prognostic significance of cell DNA content in early-stage ovarian cancer (FIGO stages I and II/A) by means of automatic image cytometryT M Wagner, A Adler, P Sevelda, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 25, 2013
Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy--findings from clinical practiceK Krzemieniecki, P Sevelda, F Erdkamp, et al.
Onkologie|October 1, 1989
Vindesine-epirubicin versus vindesine-mitoxantrone in metastatic breast cancerH Hausmaninger, M Lehnert, G Steger, et al.
Geburtshilfe Und Frauenheilkunde|June 1, 1992
[Epidermal growth factor receptor in human breast cancer: correlation with steroid receptors, tumor stage, grading and menopausal status]P Speiser, G Sliutz, R Zeillinger, et al.
British Journal of Cancer|May 1, 1993
First experience with FGF-3 (INT-2) amplification in women with epithelial ovarian cancerA Rosen, P Sevelda, M Klein, et al.
European Journal of Cancer (Oxford, England : 1990)|December 1, 1995
Randomised phase II study of epirubicin-vindesine versus mitoxantrone-vindesine in metastatic breast cancerH Hausmaninger, M Lehnert, G Steger, et al.
Pageof 15

Showing results (121-130 of 148) with videos related to

Sort By:
Pageof 15
Cancer|May 15, 1993
In vitro and in vivo evaluation of the combination of cisplatin and its analogue carboplatin for platinum dose intensification in ovarian carcinomaC Dittrich, P Sevelda, M Baur, et al.
Anticancer Research|September 1, 1994
pS2 protein status fails to be an independent prognostic factor in an average breast cancer populationP Speiser, J Stolzlechner, K Haider, et al.
Lancet (London, England)|March 3, 1990
Adjuvant tamoxifen in postmenopausal stage II breast cancer five years onJ Mikl, P Aiginger, K Czerwenka, et al.
Geburtshilfe Und Frauenheilkunde|May 1, 1991
[Effect of various factors on survival after recurrent and/or metastatic breast cancer]P Sevelda, I Kührer, C C Zielinski, et al.
International Journal of Cancer|January 15, 1994
Prognostic significance of cell DNA content in early-stage ovarian cancer (FIGO stages I and II/A) by means of automatic image cytometryT M Wagner, A Adler, P Sevelda, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 25, 2013
Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy--findings from clinical practiceK Krzemieniecki, P Sevelda, F Erdkamp, et al.
Onkologie|October 1, 1989
Vindesine-epirubicin versus vindesine-mitoxantrone in metastatic breast cancerH Hausmaninger, M Lehnert, G Steger, et al.
Geburtshilfe Und Frauenheilkunde|June 1, 1992
[Epidermal growth factor receptor in human breast cancer: correlation with steroid receptors, tumor stage, grading and menopausal status]P Speiser, G Sliutz, R Zeillinger, et al.
British Journal of Cancer|May 1, 1993
First experience with FGF-3 (INT-2) amplification in women with epithelial ovarian cancerA Rosen, P Sevelda, M Klein, et al.
European Journal of Cancer (Oxford, England : 1990)|December 1, 1995
Randomised phase II study of epirubicin-vindesine versus mitoxantrone-vindesine in metastatic breast cancerH Hausmaninger, M Lehnert, G Steger, et al.
Pageof 15